Gsk (GSK) Depreciation & Amortization (CF) (2011 - 2013)
Gsk (GSK) recorded quarterly Depreciation & Amortization (CF) of $35.6 million in Q4 2013, up 10.9% quarter-over-quarter from $32.1 million in Q4 2012, and up 10.9% on a YoY basis from $32.1 million in Q4 2012.
Gsk (GSK) Depreciation & Amortization (CF) (2011 - 2013) Analysis & Trends
Gsk's Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $35.6 million for Q4 2013.
- In Q4 2013, Depreciation & Amortization (CF) rose 10.9% year-over-year to $35.6 million; the TTM figure through Sep 2014 stood at $35.6 million (up 10.9% YoY), while the FY2018 annual figure was $1.3 billion, changed 0.11% from the prior year.
- Depreciation & Amortization (CF) was $35.6 million for Q4 2013 at Gsk, up from $32.1 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $35.6 million in Q4 2013 to a low of $32.1 million in Q4 2012.
- Historically, Depreciation & Amortization (CF) has averaged $33.6 million across 3 years, with a median of $33.0 million in 2011.
- The sharpest annual moves came in 2012 and 2013: Depreciation & Amortization (CF) decreased 2.68% in 2012, then rose 10.9% in 2013.
- A 3-year view of Depreciation & Amortization (CF) shows it stood at $33.0 million in 2011, then slipped by 2.68% to $32.1 million in 2012, then increased by 10.9% to $35.6 million in 2013.
- The last three Depreciation & Amortization (CF) figures came in at $35.6 million (Q4 2013), $32.1 million (Q4 2012), and $33.0 million (Q4 2011), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 509.00 Mn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 594.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 35.62 Mn |
| Dec 31, 2013 | 35.62 Mn |
| Dec 31, 2012 | 32.12 Mn |
| Dec 31, 2012 | 32.12 Mn |
| Dec 31, 2011 | 33.00 Mn |
| Dec 31, 2011 | 33.00 Mn |